<DOC>
	<DOCNO>NCT01697501</DOCNO>
	<brief_summary>This cross-sectional multicenter study evaluate IL28B polymorphism patient HBeAg-negative chronic hepatitis B treat Pegasys ( peginterferon alfa-2a ) predecessor ML18253 study . The study consist single visit eligible patient undergo blood test IL28B genotyping , phone follow-up 7 day visit .</brief_summary>
	<brief_title>A Study Evaluating IL28B Polymorphism Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys ( Peginterferon Alfa-2a ) Study ML18253</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Chronic hepatitis B Previous participation study ML18253 Administration least one dose study drug ML18253 study Patients satisfy inclusion criterion enrol study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>